Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 4/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL3041440 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1402964 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3041439 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL21834714 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL20733 | 1.00 | ALDH1A1 (0.94) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL10952174 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL18548768 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL17941188 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1667757 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL4191521 | 0.97 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240358612-A1 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A DYEING COMPOUND, A SEALING REAGENT AND A POST-TREATMENT AGENT | HENKEL AG & CO. KGAA (DE) | 2024-10-31 | — | — | US | disclosed |
| EP-4284329-A1 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A DYEING COMPOUND, A SEALING REAGENT AND A POST-TREATMENT AGENT | Henkel AG & Co. KGaA (DE) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022161663-A1 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A DYEING COMPOUND, A SEALING REAGENT AND A POST-TREATMENT AGENT | HENKEL AG & CO. KGAA (DE) | 2022-08-04 | — | — | WO | disclosed |
| EP-3459531-B1 | METHOD FOR PRODUCING A LAYERED TABLET | PROTINA PHARMAZEUTISCHE GMBH (DE) | 2020-10-28 | — | — | EP | disclosed |
| US-20190282475-A1 | High-Performance Hair Treatment Agents With A Proteolipid And A Magnesium Salt | HENKEL AG & CO. KGAA (DE) | 2019-09-19 | — | — | US | disclosed |
| EP-3459531-A2 | METHOD FOR PRODUCING A LAYERED TABLET | Protina Pharmazeutische Gesellschaft mbH (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-20170056311-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENT COMPIRISING AN OLIGOPEPTIDE AND A MAGNESIUM SALT | HENKEL AG & CO. KGAA (DE) | 2017-03-02 | — | — | US | disclosed |
| US-20170056305-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENTS WITH A PROTEOLIPID AND A MAGNESIUM SALT | HENKEL AG & CO. KGAA (DE) | 2017-03-02 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056305-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENTS WITH A PROTEOLIPID AND A MAGNESIUM SALT | SRRM2, PLP2, KRT18 | MEN1 1264/4885ALDH1A1 4855/4885HMGCR 721/4885 |
| US-20170056311-A1 | HIGH-PERFORMANCE HAIR TREATMENT AGENT COMPIRISING AN OLIGOPEPTIDE AND A MAGNESIUM SALT | SLC7A1, OAT, SLC26A4 | MEN1 803/4885ALDH1A1 4536/4885HMGCR 1429/4885 |
| US-20240358612-A1 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, A DYEING COMPOUND, A SEALING REAGENT AND A POST-TREATMENT AGENT | KRT18, DSG1, SCNN1A | MEN1 330/4885ALDH1A1 1159/4885HMGCR 2917/4885 |
| US-20190282475-A1 | High-Performance Hair Treatment Agents With A Proteolipid And A Magnesium Salt | SRRM2, PLP2, KRT18 | MEN1 1264/4885ALDH1A1 4855/4885HMGCR 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.